Innovative Health Initiative IHI, Call 2026

Single-Stage Call 12

The Innovative Health Initiative (IHI) is an institutionalized European partnership between the European Commission and the major industry associations of the European life sciences sector. These include, in addition to the pharmaceutical industry association EFPIA, COCIR for imaging, information technologies, and electromedicine, MedTechEurope for medical technology, EuropaBio for biotechnology, and VaccinesEurope for vaccine manufacturing.

In the single-stage, applicant-driven Call 12, five topics are launched, for which projects can be submitted without predefined thematic restrictions, provided they fit for one of the five specific objectives of the Strategic Research and Innovation Agenda (SIRA). These cross-sectoral projects address an unmet need in the field of public health.

For single-stage IHI calls, at least 45% of the eligible project costs must be contributed by the industry partners, the members of the Innovative Health Initiative associations, or the contributing partners.

What can be funded?

Are you a newcomer to Horizon Europe? Basic information is available in our  „Online Info Package: Basic Knowledge on Horizon Europe“.

The following topics are now open for submission:

Call HORIZON-JU-IHI-2026-12-single-stage

  • Topic 1: Boosting innovation for a better understanding of the determinants of health
  • Topic 2: Boosting innovation through better integration of fragmented health R&I efforts
  • Topic 3: Boosting innovation for people-centred integrated healthcare solutions
  • Topic 4: Boosting innovation through exploitation of digitalisation and data exchange in healthcare
  • Topic 5: Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions

You will find all details for the current Call at the Funding & Tenders Portal of the European Commission.

Who can be funded?

Funding is provided to European consortia consisting of several (usually at least three) organizations from three different countries, as specified in the call documents of the European Commission.

For this call, an exception applies:

  • United Kingdom and Canada: Applicants from these countries are eligible for funding under Topics 1, 2, 3, and 5, but not under Topic 4.
  • Switzerland and South Korea: Applicants from these countries are eligible for funding under Topics 1, 2, and 3, but not under Topics 4 and 5.

What is the amount of funding?

The amount of funding for individual projects depends on the topic. A total budget of EUR 163.1 million is available for this Call.

What are the submission criteria?

Submission criteria are described in the Call documents of the Innovative Health Initiative.

How does the submission work?

Projects are submitted via the Funding and Tenders Portal of the European Commission.

When will a decision be made?

Results out of this Call are expected in summer 2026.
Closed Submission Period
15.01.2026 - 21.04.2026, 17:00 hour
Funding procedure
Submission with a proposal process
Target group
(Non-profit) AssociationsAuthoritiesCompetence centresLarge companiesMultipliers / IntermediariesResearch facilitiesSmall and medium-sized enterprises (SMEs)Start UpUniversitiesUniversities of applied sciences
Collaboration
Required
Scope
European & International
Eligible costs
Facility usage costsMaterial and supply costsPersonnel costsThird-party costsTravel expenses
Funder
EC - European Commission

Ines HABERL

Nationale Kontaktstelle
Cluster 1 und Mission Cancer
+43 577 55-4103 E-Mail

Further offers

Scope filters

Scope filters

39 Results
Selected filters
OpenX

About the FFG

The Austrian Research Promotion Agency (FFG) is the national funding institution for industry-related research and development in Austria. FFG funding plays a key role in generating new knowledge, developing new products and services, and thereby becoming more competitive in the global market.
Learn more

Stay connected

Every week, you will receive an update from the FFG in your inbox. Of course, you can unsubscribe from our newsletter at any time.